益丰药房(603939) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 reached ¥5,266,053,201.98, representing a year-on-year increase of 26.94%[3] - The net profit attributable to shareholders was ¥336,477,177.44, reflecting a growth of 23.60% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses was ¥321,446,423.67, which is a 20.80% increase year-on-year[3] - The basic earnings per share for the period was ¥0.47, up by 23.68% from the previous year[3] - Total revenue for Q1 2023 reached ¥5,266,053,201.98, a 27.0% increase from ¥4,148,494,215.04 in Q1 2022[20] - Net profit for Q1 2023 was ¥379,869,656.04, representing a 25.8% increase compared to ¥301,846,217.02 in Q1 2022[22] - Total profit for Q1 2023 was ¥500,816,745.84, up from ¥407,279,978.80 in Q1 2022, indicating a 23.0% growth[22] - Comprehensive income total for Q1 2023 was ¥470,476,565.53, compared to ¥301,846,217.02 in Q1 2022, showing a 55.9% increase[22] Cash Flow - The net cash flow from operating activities was ¥1,288,846,164.43, showing a significant increase of 98.87%[3] - Cash flow from operating activities for Q1 2023 was ¥1,288,846,164.43, a significant increase from ¥648,087,580.21 in Q1 2022[23] - The net cash flow from investing activities was -$1,313,579,823.08, compared to -$545,566,623.69 in the previous year, indicating a significant increase in cash outflow for investments[24] - The total cash outflow from investing activities was $1,381,141,313.01, compared to $614,232,584.77 in the same period last year, reflecting a substantial increase[24] - The net cash flow from financing activities was -$341,525,797.58, slightly higher than -$338,683,047.06 in the previous year[24] - The net decrease in cash and cash equivalents was -$366,259,456.23, compared to -$236,162,090.54 in the previous year, indicating a worsening cash position[24] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥21,399,378,617.37, a 1.71% increase from the end of the previous year[4] - The total assets as of March 31, 2023, amounted to 21,399,378,617.37 RMB, an increase from 21,038,886,640.04 RMB at the end of 2022[16] - The total liabilities as of March 31, 2023, were 11,774,060,177.95 RMB, down from 11,917,419,653.19 RMB at the end of 2022[17] - The company's cash and cash equivalents decreased to 3,571,532,389.09 RMB from 4,112,519,204.66 RMB at the end of 2022, reflecting a decline of approximately 13.2%[15] - The company's accounts receivable decreased to 1,285,324,434.99 RMB from 1,843,940,879.13 RMB, a reduction of about 30.3%[15] - The company's equity attributable to shareholders increased to 9,013,837,501.90 RMB from 8,556,078,527.92 RMB, representing a growth of approximately 5.3%[17] Store Expansion and Mergers - In Q1 2023, the company added 661 new stores, including 308 self-built stores, 154 acquired stores, and 199 franchised stores, resulting in a total of 10,865 stores, a net increase of 597 stores compared to the previous period[10] - The company completed 4 mergers and acquisitions in the industry during the reporting period, with 3 projects finalized, including the acquisition of 100% equity of a new company for 113 million RMB involving 54 stores and 8 clinics[11] Research and Development - Research and development expenses for Q1 2023 were ¥4,637,452.27, slightly up from ¥4,174,752.27 in Q1 2022[20] Other Financial Metrics - Non-recurring gains and losses for the period totaled ¥15,030,753.77, after accounting for tax and minority interests[5] - The weighted average return on equity increased by 0.28 percentage points to 3.85%[3] - The company reported a total inventory of 3,488,889,401.55 RMB, a slight decrease from 3,614,549,276.03 RMB at the end of 2022[15] - The company’s long-term equity investments stood at 5,249,082.40 RMB, remaining stable compared to the previous period[16] - The company’s total non-current assets increased to 10,942,725,254.65 RMB from 10,460,663,228.00 RMB, indicating a growth of approximately 4.6%[16] - Other comprehensive income after tax for Q1 2023 was ¥90,606,909.49, with no previous year comparison available[22]